Valuation: Berkley Renewables Inc.

Market Cap 4L 3L 3L 3L 5L 3.51Cr 5L 35.34L 13.81L 1.73Cr 13.68L 13.38L 5.97Cr P/E 2016
4.22x
P/E 2017 -1.16x
Enterprise Value 51.26L 45.02L 41.87L 38.42L 72.18L 49Cr 73.3L 4.97Cr 1.94Cr 24Cr 1.92Cr 1.88Cr 84Cr EV / Sales 2016
3.53x
EV / Sales 2017 3.18x
Free-Float
90.7%
Yield 2016 *
-
Yield 2017 -
Manager TitleAgeSince
Chief Executive Officer 63 20/06/2002
Director of Finance/CFO - -
Director TitleAgeSince
Chairman 63 -
Director/Board Member 66 17/08/2006
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 5L
+0.05%+4.84%+26.66%+2.94% 15TCr
-1.09%+6.61%+52.24%+65.46% 9.67TCr
+0.62%+4.65%+23.65%+13.20% 7.8TCr
-0.39%+4.67%+41.54%+41.17% 5.76TCr
-0.52%+4.45%+28.16%-8.83% 5.7TCr
-1.36%+5.36%+108.06%+73.46% 5.49TCr
-0.55%+2.76%+36.73%-15.26% 5.19TCr
-2.93%+1.68%+19.97%-17.08% 4.3TCr
-0.67%+7.00%+1.61%+27.72% 3.32TCr
Average -1.33%+4.66%+37.62%+20.31% 6.19TCr
Weighted average by Cap. -1.28%+5.13%+38.06%+21.14%

Financials

2016 2017
Net sales 10.34L 9L 8L 8L 14.56L 9.96Cr 14.79L 1Cr 39.18L 4.9Cr 38.82L 37.98L 17Cr 17.25L 15.15L 14.09L 12.93L 24.29L 17Cr 24.66L 1.67Cr 65.36L 8.17Cr 64.75L 63.35L 28Cr
Net income 2L 2L 1L 1L 2L 1.66Cr 2L 16.75L 7L 81.77L 6L 6L 2.83Cr -6L -6L -5L -5L -9L -6.07Cr -9L -61.15L -23.89L -2.99Cr -23.67L -23.16L -10Cr
Net Debt 29.17L 25.62L 23.83L 21.86L 41.08L 28Cr 41.71L 2.83Cr 1.11Cr 14Cr 1.1Cr 1.07Cr 48Cr 47.61L 41.82L 38.89L 35.69L 67.05L 46Cr 68.08L 4.62Cr 1.8Cr 23Cr 1.79Cr 1.75Cr 78Cr
Logo Berkley Renewables Inc.
Berkley Renewables Inc. is a Canada-based, growth-oriented diversified issuer also pursuing renewable energy opportunities, primarily in the solar energy sector. The Company is pursuing solar energy investments in Ontario, Canada. It is also engaged in developing autologous cell therapies to treat conditions linked to a deficit of healthy cells required for normal healing and function through RepliCel Life Sciences Inc. The Company's RCT-01, RCS-01, and RCH-01 cell therapies are designed to treat chronic tendinosis, damaged or aged skin and pattern baldness. The Company is also developing a proprietary injection device (RCI) for optimal clinical delivery. The Company is developing solar photovoltaic (PV) projects in Ontario, Canada, through its subsidiary, Solar Flow-Through General Partnership. Working with Solar Flow-Through, the Company has also developed a flow-through investment vehicle for investors to participate in Ontario's solar energy growth.
Employees
-